Metastatic breast cancer

The role of chemotherapy

Jr Sledge G.W., Kathy Miller

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalSeminars in Oncology
Volume26
Issue number1 SUPPL. 2
StatePublished - 1999
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Taxoids
Therapeutics
Salvage Therapy
Stem Cell Transplantation
Drug Discovery
Appointments and Schedules
Morbidity
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Metastatic breast cancer : The role of chemotherapy. / Sledge G.W., Jr; Miller, Kathy.

In: Seminars in Oncology, Vol. 26, No. 1 SUPPL. 2, 1999, p. 6-10.

Research output: Contribution to journalArticle

Sledge G.W., J & Miller, K 1999, 'Metastatic breast cancer: The role of chemotherapy', Seminars in Oncology, vol. 26, no. 1 SUPPL. 2, pp. 6-10.
Sledge G.W., Jr ; Miller, Kathy. / Metastatic breast cancer : The role of chemotherapy. In: Seminars in Oncology. 1999 ; Vol. 26, No. 1 SUPPL. 2. pp. 6-10.
@article{8fe5acdaf62149a4b914801ba200d87d,
title = "Metastatic breast cancer: The role of chemotherapy",
abstract = "Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.",
author = "{Sledge G.W.}, Jr and Kathy Miller",
year = "1999",
language = "English (US)",
volume = "26",
pages = "6--10",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Metastatic breast cancer

T2 - The role of chemotherapy

AU - Sledge G.W., Jr

AU - Miller, Kathy

PY - 1999

Y1 - 1999

N2 - Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.

AB - Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033002487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033002487&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 6

EP - 10

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -